Gastrin-releasing peptide receptor antagonist effects on an animal model of sepsis

Rationale: Several new therapeutic strategies have been described for the treatment of sepsis, but to date none are related to alterations in the bombesin/gastrin-releasing peptide (GRP) receptor pathways. Objectives: To determine the effects of a selective GRP receptor antagonist, RC-3095, on cytokine release from macrophages and its in vivo effects in the cecal ligation and puncture (CLIP) model of sepsis and in acute lung injury induced by intratracheal instillation of LIPS. Methods: We determined the effects of RC-3095 in the CLIP model of sepsis and in acute lung injury induced by intratracheal instillation of LIPS. In addition, we determined the effects of RC-3095 on tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta, IL-10, and nitric oxide release from activated macrophages. Measurements and Main Results: The GRP antagonist attenuated LPS-or CLP-induced TNF-alpha, IL-10, and nitric oxide release in cultured macrophages and decreased the mRNA levels of inducible nitric oxide synthase. The administration of RC-3095 (0.3 mg/kg) 6 h after sepsis induction improved survival in the CLIP model, and diminished lung damage after intratracheal instillation of LIPS. These effects were associated with attenuation on the circulating TNF-alpha and IL-1 beta levels and decreased myeloperoxidase activity in several organs. Conclusions: We report that a selective GRP receptor antagonist attenuates the release of proinflammatory cytokines in vitro and in vivo and improves survival in "established" sepsis. These-are consistent with the involvement of a new inflammatory pathway relevant to the development of sepsis.